Text Size

Cost-Utility Analysis of a Latanoprost Cationic Emulsion (STN1013001) versus Other Latanoprost in the Treatment of Open-Angle Glaucoma or Ocular Hypertension and Concomitant Ocular Surface Disease in Germany

Lazzaro, C.; van Steen, C.; Billeit, S.; Frauenknecht, H.; Kallen, C.; Pfennigsdorf, S.; Thelen, U.; Angelillo, L.


  • 2022
  • Clinical Ophthalmology
View publication
  • Therapeutic Area

    Glaucoma

  • Affiliations

    Health Economist and Research Director, Studio di Economia Sanitaria, Milan, Italy; Santen GmbH, München, Germany; Private Practicing Ophthalmologist, Lübeck, Germany; Private Practicing Ophthalmologist, Treuchtlingen, Germany; Private Practicing Ophthalmologist, Krefeld, Germany; Private Practicing Ophthalmologist, Polch, Germany; Private Practicing Ophthalmologist, Münster, Germany; University Hospital Muenster, Department of Ophthalmology, Münster, Germany

Related Publications

Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial

Wang T.H.; Aung T.; Lu D.-W.; George R.; Senthil S.; Lu F.; Odani-Kawabata N.; Park K.H.


Efficacy and Safety of a Preservative-Free Latanoprost Cationic Emulsion in Patients with Open-Angle Glaucoma and Concurrent Ocular Surface Disease: A Randomized Phase 2 Study.

Bacharach, Jason; McLaurin, Eugene B.; Silverstein, Steven; Amrane, Mourad; Garrigue, Jean-Sebastien; Ismail, Dahlia; Flynn, William J.; Catiolanze Phase 2 study group


Assessment of Brain-Derived Neurotrophic Factor on Retinal Structure and Visual Function in Rodent Models of Optic Nerve Crush

Taniguchi T.; Sharif N.A.; Ota T.; Farjo R.A.; Rausch R.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022